http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 06 Mar 2026 17:04:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++INCYTE+CORP+++++++++++++++For%3A+Feb+27/26126506.html si-local-file:///var/storage/secattach/20260306/26126506.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++INCYTE+CORP+++++++++++++++For%3A+Feb+27/26126506.html Fri, 06 Mar 2026 17:04:00 -0500 INCY O.00160346 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++INCYTE+CORP+++++++++++++++For%3A+Feb+27/26126506.html si-local-file:///var/storage/secattach/20260306/26126506.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++INCYTE+CORP+++++++++++++++For%3A+Feb+27/26126506.html Fri, 06 Mar 2026 17:04:00 -0500 INCY O.00160346 http://www.streetinsider.com/Corporate+News/Incyte+receives+European+approval+for+Zynyz+anal+cancer+treatment/26126176.html <p>Incyte (NASDAQ: INCY) announced that the European Commission has approved Zynyz (retifanlimab) in combination with carboplatin and paclitaxel for first-line treatment of adult patients with metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canal.</p><p>The approval makes Zynyz the first systemic treatment for advanced squamous cell carcinoma of the anal canal in Europe. The decision follows a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use in January 2026.</p><p>The approval is based on results from the Phase 3 POD1UM-303/InterAACT2 trial, which demonstrated a 37% reduction in the risk of progression or death compared http://www.streetinsider.com/Corporate+News/Incyte+receives+European+approval+for+Zynyz+anal+cancer+treatment/26126176.html Fri, 06 Mar 2026 16:42:36 -0500 INCY http://www.streetinsider.com/FDA/Incyte+receives+European+approval+for+Zynyz+anal+cancer+treatment/26126176.html <p>Incyte (NASDAQ: INCY) announced that the European Commission has approved Zynyz (retifanlimab) in combination with carboplatin and paclitaxel for first-line treatment of adult patients with metastatic or inoperable locally recurrent squamous cell carcinoma of the anal canal.</p><p>The approval makes Zynyz the first systemic treatment for advanced squamous cell carcinoma of the anal canal in Europe. The decision follows a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use in January 2026.</p><p>The approval is based on results from the Phase 3 POD1UM-303/InterAACT2 trial, which demonstrated a 37% reduction in the risk of progression or death compared http://www.streetinsider.com/FDA/Incyte+receives+European+approval+for+Zynyz+anal+cancer+treatment/26126176.html Fri, 06 Mar 2026 16:42:36 -0500 INCY http://www.streetinsider.com/Press+Releases/Incyte+Announces+the+European+Commission+Approval+of+Zynyz%C2%AE+%28retifanlimab%29+for+the+First-Line+Treatment+of+Advanced+Squamous+Cell+Carcinoma+of+the+Anal+Canal+%28SCAC%29/26126165.html <p class="bwmarginl1"> - <i>Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe</i> </p><p class="bwmarginl1"> <i>- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1</i> </p> <p> WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with http://www.streetinsider.com/Press+Releases/Incyte+Announces+the+European+Commission+Approval+of+Zynyz%C2%AE+%28retifanlimab%29+for+the+First-Line+Treatment+of+Advanced+Squamous+Cell+Carcinoma+of+the+Anal+Canal+%28SCAC%29/26126165.html Fri, 06 Mar 2026 16:42:00 -0500 A.60012004 A.60012012 INCY O.00160346 O.01304637 O.20847516 http://www.streetinsider.com/Press+Releases/Incyte+Announces+the+European+Commission+Approval+of+Zynyz%C2%AE+%28retifanlimab%29+for+the+First-Line+Treatment+of+Advanced+Squamous+Cell+Carcinoma+of+the+Anal+Canal+%28SCAC%29/26126165.html <p class="bwmarginl1"> - <i>Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe</i> </p><p class="bwmarginl1"> <i>- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1</i> </p> <p> WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with http://www.streetinsider.com/Press+Releases/Incyte+Announces+the+European+Commission+Approval+of+Zynyz%C2%AE+%28retifanlimab%29+for+the+First-Line+Treatment+of+Advanced+Squamous+Cell+Carcinoma+of+the+Anal+Canal+%28SCAC%29/26126165.html Fri, 06 Mar 2026 16:42:00 -0500 A.60012004 A.60012012 INCY O.00160346 O.01304637 O.20847516 http://www.streetinsider.com/Press+Releases/Incyte+Announces+the+European+Commission+Approval+of+Zynyz%C2%AE+%28retifanlimab%29+for+the+First-Line+Treatment+of+Advanced+Squamous+Cell+Carcinoma+of+the+Anal+Canal+%28SCAC%29/26126165.html <p class="bwmarginl1"> - <i>Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe</i> </p><p class="bwmarginl1"> <i>- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1</i> </p> <p> WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with http://www.streetinsider.com/Press+Releases/Incyte+Announces+the+European+Commission+Approval+of+Zynyz%C2%AE+%28retifanlimab%29+for+the+First-Line+Treatment+of+Advanced+Squamous+Cell+Carcinoma+of+the+Anal+Canal+%28SCAC%29/26126165.html Fri, 06 Mar 2026 16:42:00 -0500 A.60012004 A.60012012 INCY O.00160346 O.01304637 O.20847516 http://www.streetinsider.com/Press+Releases/Incyte+Announces+the+European+Commission+Approval+of+Zynyz%C2%AE+%28retifanlimab%29+for+the+First-Line+Treatment+of+Advanced+Squamous+Cell+Carcinoma+of+the+Anal+Canal+%28SCAC%29/26126165.html <p class="bwmarginl1"> - <i>Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe</i> </p><p class="bwmarginl1"> <i>- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1</i> </p> <p> WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with http://www.streetinsider.com/Press+Releases/Incyte+Announces+the+European+Commission+Approval+of+Zynyz%C2%AE+%28retifanlimab%29+for+the+First-Line+Treatment+of+Advanced+Squamous+Cell+Carcinoma+of+the+Anal+Canal+%28SCAC%29/26126165.html Fri, 06 Mar 2026 16:42:00 -0500 A.60012004 A.60012012 INCY O.00160346 O.01304637 O.20847516 http://www.streetinsider.com/Press+Releases/Incyte+Announces+the+European+Commission+Approval+of+Zynyz%C2%AE+%28retifanlimab%29+for+the+First-Line+Treatment+of+Advanced+Squamous+Cell+Carcinoma+of+the+Anal+Canal+%28SCAC%29/26126165.html <p class="bwmarginl1"> - <i>Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe</i> </p><p class="bwmarginl1"> <i>- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1</i> </p> <p> WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with http://www.streetinsider.com/Press+Releases/Incyte+Announces+the+European+Commission+Approval+of+Zynyz%C2%AE+%28retifanlimab%29+for+the+First-Line+Treatment+of+Advanced+Squamous+Cell+Carcinoma+of+the+Anal+Canal+%28SCAC%29/26126165.html Fri, 06 Mar 2026 16:42:00 -0500 A.60012004 A.60012012 INCY O.00160346 O.01304637 O.20847516 http://www.streetinsider.com/Press+Releases/Incyte+Announces+the+European+Commission+Approval+of+Zynyz%C2%AE+%28retifanlimab%29+for+the+First-Line+Treatment+of+Advanced+Squamous+Cell+Carcinoma+of+the+Anal+Canal+%28SCAC%29/26126165.html <p class="bwmarginl1"> - <i>Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe</i> </p><p class="bwmarginl1"> <i>- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1</i> </p> <p> WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with http://www.streetinsider.com/Press+Releases/Incyte+Announces+the+European+Commission+Approval+of+Zynyz%C2%AE+%28retifanlimab%29+for+the+First-Line+Treatment+of+Advanced+Squamous+Cell+Carcinoma+of+the+Anal+Canal+%28SCAC%29/26126165.html Fri, 06 Mar 2026 16:42:00 -0500 A.60012004 A.60012012 INCY O.00160346 O.01304637 O.20847516 http://www.streetinsider.com/Business+Wire/Incyte+Announces+the+European+Commission+Approval+of+Zynyz%C2%AE+%28retifanlimab%29+for+the+First-Line+Treatment+of+Advanced+Squamous+Cell+Carcinoma+of+the+Anal+Canal+%28SCAC%29/26126165.html <p class="bwmarginl1"> - <i>Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe</i> </p><p class="bwmarginl1"> <i>- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1</i> </p> <p> WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with http://www.streetinsider.com/Business+Wire/Incyte+Announces+the+European+Commission+Approval+of+Zynyz%C2%AE+%28retifanlimab%29+for+the+First-Line+Treatment+of+Advanced+Squamous+Cell+Carcinoma+of+the+Anal+Canal+%28SCAC%29/26126165.html Fri, 06 Mar 2026 16:42:00 -0500 A.60012004 A.60012012 INCY O.00160346 O.01304637 O.20847516 http://www.streetinsider.com/Business+Wire/Incyte+Announces+the+European+Commission+Approval+of+Zynyz%C2%AE+%28retifanlimab%29+for+the+First-Line+Treatment+of+Advanced+Squamous+Cell+Carcinoma+of+the+Anal+Canal+%28SCAC%29/26126165.html <p class="bwmarginl1"> - <i>Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe</i> </p><p class="bwmarginl1"> <i>- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1</i> </p> <p> WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with http://www.streetinsider.com/Business+Wire/Incyte+Announces+the+European+Commission+Approval+of+Zynyz%C2%AE+%28retifanlimab%29+for+the+First-Line+Treatment+of+Advanced+Squamous+Cell+Carcinoma+of+the+Anal+Canal+%28SCAC%29/26126165.html Fri, 06 Mar 2026 16:42:00 -0500 A.60012004 A.60012012 INCY O.00160346 O.01304637 O.20847516 http://www.streetinsider.com/Business+Wire/Incyte+Announces+the+European+Commission+Approval+of+Zynyz%C2%AE+%28retifanlimab%29+for+the+First-Line+Treatment+of+Advanced+Squamous+Cell+Carcinoma+of+the+Anal+Canal+%28SCAC%29/26126165.html <p class="bwmarginl1"> - <i>Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe</i> </p><p class="bwmarginl1"> <i>- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1</i> </p> <p> WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with http://www.streetinsider.com/Business+Wire/Incyte+Announces+the+European+Commission+Approval+of+Zynyz%C2%AE+%28retifanlimab%29+for+the+First-Line+Treatment+of+Advanced+Squamous+Cell+Carcinoma+of+the+Anal+Canal+%28SCAC%29/26126165.html Fri, 06 Mar 2026 16:42:00 -0500 A.60012004 A.60012012 INCY O.00160346 O.01304637 O.20847516 http://www.streetinsider.com/Business+Wire/Incyte+Announces+the+European+Commission+Approval+of+Zynyz%C2%AE+%28retifanlimab%29+for+the+First-Line+Treatment+of+Advanced+Squamous+Cell+Carcinoma+of+the+Anal+Canal+%28SCAC%29/26126165.html <p class="bwmarginl1"> - <i>Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe</i> </p><p class="bwmarginl1"> <i>- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1</i> </p> <p> WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with http://www.streetinsider.com/Business+Wire/Incyte+Announces+the+European+Commission+Approval+of+Zynyz%C2%AE+%28retifanlimab%29+for+the+First-Line+Treatment+of+Advanced+Squamous+Cell+Carcinoma+of+the+Anal+Canal+%28SCAC%29/26126165.html Fri, 06 Mar 2026 16:42:00 -0500 A.60012004 A.60012012 INCY O.00160346 O.01304637 O.20847516 http://www.streetinsider.com/Business+Wire/Incyte+Announces+the+European+Commission+Approval+of+Zynyz%C2%AE+%28retifanlimab%29+for+the+First-Line+Treatment+of+Advanced+Squamous+Cell+Carcinoma+of+the+Anal+Canal+%28SCAC%29/26126165.html <p class="bwmarginl1"> - <i>Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe</i> </p><p class="bwmarginl1"> <i>- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1</i> </p> <p> WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with http://www.streetinsider.com/Business+Wire/Incyte+Announces+the+European+Commission+Approval+of+Zynyz%C2%AE+%28retifanlimab%29+for+the+First-Line+Treatment+of+Advanced+Squamous+Cell+Carcinoma+of+the+Anal+Canal+%28SCAC%29/26126165.html Fri, 06 Mar 2026 16:42:00 -0500 A.60012004 A.60012012 INCY O.00160346 O.01304637 O.20847516 http://www.streetinsider.com/Business+Wire/Incyte+Announces+the+European+Commission+Approval+of+Zynyz%C2%AE+%28retifanlimab%29+for+the+First-Line+Treatment+of+Advanced+Squamous+Cell+Carcinoma+of+the+Anal+Canal+%28SCAC%29/26126165.html <p class="bwmarginl1"> - <i>Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe</i> </p><p class="bwmarginl1"> <i>- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1</i> </p> <p> WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with http://www.streetinsider.com/Business+Wire/Incyte+Announces+the+European+Commission+Approval+of+Zynyz%C2%AE+%28retifanlimab%29+for+the+First-Line+Treatment+of+Advanced+Squamous+Cell+Carcinoma+of+the+Anal+Canal+%28SCAC%29/26126165.html Fri, 06 Mar 2026 16:42:00 -0500 A.60012004 A.60012012 INCY O.00160346 O.01304637 O.20847516 http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0500 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0500 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0500 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0500 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0500 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0500 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0500 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0500 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.nv.lasveg" idsrc="xmltag.org" >LAS VEGAS</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <b><i>The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/<span value="ACORN:3216571029" idsrc="xmltag.org" >OHARA Pharmaceutical</span>), Tovecimig (CTX-009) (<span value="NASDAQ-NMS:CMPX" idsrc="xmltag.org" >Compass Therapeutics</span>), Lenvatinib mesylate (LENVIMA) (<span value="NYSE:MRK" idsrc="xmltag.org" >Merck</span>/Eisai), and others will further boost the market growth.</i></b></p> <div id="prni_dvprnejpg7689left" dir="ltr" style="width: 100%; text-align: left;"><img id="prnejpg7689left" title="DelveInsight Logo" src="https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg" alt="DelveInsight Logo" align="middle" /></div><p>Recently published Biliary Tract http://www.streetinsider.com/Press+Releases/Biliary+Tract+Cancer+Market+is+Predicted+to+Exhibit+Remarkable+Growth+at+a+CAGR+of+10.1%25+During+the+Forecast+Period+%282025-2034%29+%7C+DelveInsight/26094077.html Mon, 02 Mar 2026 17:31:00 -0500 2RH A.20986375 A.21423504 A.32165710 A.33353809 A.34272207 A.39985803 A.40151759 A.50100157 A.50113798 A.50113881 A.50114197 A.50202178 A.50202556 A.60012004 BOLD CMPX INCY JAZZ LLY LOXO MRK O.00000313 O.00002198 O.00037438 O.00050368 O.00052901 O.00160346 O.00160456 O.00637617 O.00644488 O.00823584 O.01304637 O.03044482 O.07639287 O.08528768 O.12498162 O.13804664 O.15817313 O.18722415 O.38725784 O.39100698 O.40271399 O.49925668 O.51354437 O.54940956 O.55342982 PFE RDHL REPL RLAY ROG S1GE34 SGEN